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Abstract
Overwhelming evidence from observational epidemiological studies indicates that herpes simplex
virus type 2 (HSV-2) infection enhances the risk of acquiring HIV infection. Studies of genital shedding
of HIV have suggested that HSV-2 infection also increases the onward transmission of HIV-1 by HIV/
HSV-2 co-infected patients. Several randomized controlled trials were initiated to assess the impact
of HSV-2 suppressive therapy on the acquisition of HIV infection by HSV-2 infected men and women,
and on the onward transmission of HIV by HSV-2/HIV co-infected men and women. In the past
2 years the results of these trials have been published. HSV-2 suppressive therapy was not found to
have any effect on HIV acquisition nor on onward transmission of HIV. However, suppressive therapy
with acyclovir was found to slow down disease progression in HIV/HSV-2 co-infected patients. The
effect was rather modest and cost-effectiveness studies are needed to assess whether HSV-2
suppressive therapy has a place in the management of HIV-1 infected patients, especially in low and
middle income countries.
Introduction and context
The World Health Organization and The United Nations
Joint Programme on HIV/AIDS (UNAIDS) estimated
that in 2008, 2.7 million people became newly infected
with HIV, of whom 1.9 million were living in sub-
Saharan Africa [1]. Since the beginning of this century,
considerable progress has been made in the scaling up of
antiretroviral treatment in low and middle income
countries. However, coverage remains suboptimal and
new HIV infections continue to outnumber patients who
are put on antiretroviral treatment [2]. It is clear that HIV
treatment programs are not sustainable unless the tide of
new HIV infections is stemmed.
Strategies to reduce the spread of HIV infection can be
broadly categorized into behavioural interventions and
biomedical interventions. The latter interventions aim to
reduce the probability of transmission of HIV during
sexual intercourse and one of the most promising
interventions in this field was the control of other
sexually transmitted infections (STIs) as they have been
shown to facilitate the transmission of HIV [3]. Several
randomized trials have been conducted to assess the
impact of STI control on the incidence of HIV infection,
with conflicting results. It appeared that the impact of STI
control on the spread of HIV is dependent on the stage of
the HIV epidemic, with a larger impact in earlier stages of
the epidemic[4]. Moreover, it became clear that infection
with herpes simplex virus type 2 (HSV-2) a viral STI that
cannot be controlled by early detection and treatment of
infected persons, plays an overwhelming role in the
spread of HIV, especially in sub-Saharan Africa, where
the prevalence of HSV-2 infection in adults in the general
population ranges from 30% to 80% in women and
from 10% to 50% in men [5]. A meta-analysis of
longitudinal studies found that men and women who
are infected with HSV-2 have a three-fold increased risk
of acquiring HIV infection [6]. Using this relative risk and
data on prevalence of HSV-2 infection, it has been
estimated that in sub-Saharan Africa,38-60% of new HIV
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men may be attributable to HSV-2 infection [6]. In
addition, studies on shedding of HIV and HSV-2 in the
genital tract have shown that reactivation of HSV-2
infection is associated with increased shedding of HIV,
suggesting that HSV-2 infection increases the infectivity
of HIV/HSV-2 co-infected men and women [7-10].
A reduction in incidence and prevalence of HSV-2
infection could thus have a considerable impact on the
incidence of HIV infection. However, apart from
behaviour change interventions and condom use, there
are very few options to control HSV-2 infection with
biomedical interventions. The only vaccine with some
proven efficacy prevents HSV-2 acquisition in women
who are not infected with HSV-1, but does not prevent
acquisition in men, or in women who are infected with
HSV-1 [11]. This vaccine is thus of very limited use in low
and middle income countries where the prevalence of
HSV-1 among young people and adults is still very high.
To date the only alternative strategy is suppressive
therapy with acyclovir or valacyclovir, which has been
shown to decrease episodes of reactivation of HSV-2
infection and transmission of HSV-2 [12,13]. Several
randomized controlled trials were initiated to assess the
impact of HSV-2 suppressive therapy on the acquisition
of HIV infection by HSV-2infected men and women, and
on the onward transmission of HIV by HSV-2/HIV co-
infected men and women. In the past 2 years the results
of these trials have been published, and it is time now to
take stock.
Recent advances
Does suppressive therapy reduce the risk of HIV infection
in HSV-2 infected men and women?
Two trials have assessed the effect of HSV-2 suppressive
treatment with acyclovir 400 mg twice daily on HIV
acquisition [14,15]. Study populations included women
in Tanzania athigh risk of HIV infection;women atlower
risk of HIV infection in South Africa, Zimbabwe and
Zambia; and men who have sex with men in Peru and in
the USA. Suppressive treatment with acyclovir reduced
the incidence of genital ulcerations but did not have any
effect on HIV incidence (Table 1).
Whenever the results of a trial are negative, two major
questions are raised: (a) was the intervention that was
tested the right one; and (b) was there an effect that was
not measured? The above trials were powered to detect a
50% protective effect of suppressive therapy with
acyclovir and had sufficient endpoints to detect such
effect. The two trials might have missed a modest effect
of more limited public health significance. Suboptimal
adherence to the study drugs could have attenuated any
difference in HIV incidence between the two study arms.
In both trials very high adherence levels were achieved.
In the Tanzanian trial there was an effect in those women
who took more than 90% of the prescribed medication,
but it was not statistically significant (rate ratio 0.58,
95% confidence interval [CI] 0.25-1.38) and such effect
was not found in the trial by Celum et al. [15] (hazard
ratio [HR] 1.0, 95% CI 0.67-1.50).
The most likely explanation for the lack of effect is that
the intervention was not right. The authors of both
papers considered the possibility that valacyclovir or
higher dose acyclovir might have been a better choice for
suppressive therapy. Studies on the effects on herpes
recurrences of acyclovir and of valacyclovir, however,
suggest that both drugs may have similar effects and that
it is unlikely that a larger impact on HIV incidence would
have been found with valacyclovir. The most likely
explanation is that the concept of the intervention was
not right and that suppressing clinical and subclinical
reactivation of HSV-2 infection is not enough to reduce
the vulnerability to HIV infection associated with HSV-2
infection. Indeed, a study published in 2009 found
evidence that HIV receptor-positive inflammatory cells
persist in the genitalia for a very long time after healing
of reactivation [16].
Table 1. Summary of trials that assessed the impact of suppressive therapy with acyclovir on HIV acquisition
Incidence of HIV per 100 pyr
Study population Site Total (n) enrolled Treatment group Placebo group Rate ratio/HR (95% CI) Reference
Women at higher
risk of HIV
Tanzania 821 4.44 4.12 1.08 (0.64-1.83) [7]
Women at lower
risk of HIV
South Africa,
Zimbabwe, Zambia
1358 4.9 3.1 1.53 (0.95-2.46) [8]
MSM Peru 1355 3.2 3.8 0.82 (0.48-1.41) [8]
USA 459 2.5 2.2 1.09 (0.36-3.24)
CI, confidence interval; HR, hazard ration; MSM, men who have sex with men; pyr, person-years.
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HIV infection by HSV-2/HIV co-infected men and women?
Several randomized trials published in recent years
found that suppressive therapy with acyclovir or
valacyclovir reduced plasma HIV viral load and genital
shedding of HIV-1 RNA in HIV-infected women and men
who were co-infected with HSV-2 [17-21]. This suggests
that suppressive therapy of HSV-2 infection could reduce
the infectivity of HIV/HSV-2 co-infected persons. How-
ever, the proof of the pudding is in the eating. The
Partners in Prevention HSV/HIV Transmission Study
directly assessed the effects of suppressive therapy with
acyclovir on onward transmission of HIV from an HIV/
HSV-2 co-infected person to his/her HIV uninfected
stable partner [22]. Study participants taking 400 mg
acyclovir twice daily had significantly less episodes of
genital ulcers than study participants in the placebo
group. They also had a significantly lower plasma HIV
viral load. Yet, there was no difference in HIV transmis-
sion: in the intention-to-treat analysis the incidence of
HIV infection was the same in the intervention group
and the placebo group, 2.7 per 100 person-years (HR
0.99, 95% CI 0.71-1.40).
The study was powered to detect a 50% reduction in HIV
transmission, so a modest effect might have been missed
that would have been of limited public health signifi-
cance. The most likely explanation for the disappointing
result is that the reduction in plasma HIV viral load was
just not enough to reduce infectivity. During the follow-
up period the mean plasma viral load was 0.25 log lower
in the acyclovir group compared to the placebo group
[22]. An observational study of HIV discordant couples
in Uganda suggests that larger reductions in plasma viral
load are needed to have a substantial effect on onward
transmission of HIV. In this study the mean plasma viral
load was 4.48 log in HIV-1 infected subjects whose
partner seroconverted and 3.89 log in HIV-1 infected
subjects whose partner did not seroconvert [23].
The Partners in Prevention HSV/HIV Transmission Study
was also the first study that directly assessed the long-
term effects of HSV-2 suppressive therapy on disease
progression [24]. In the patients who took acyclovir, the
decline in CD4 cell count was slower, initiation of
antiretroviral treatment was delayed, and mortality was
reduced compared with patients in the control group.
Implications for clinical practice
The trials with HSV-2 suppressive therapy have not
found any effect on HIV acquisition nor on HIV
transmission. Consequently, suppressive therapy with
acyclovir and valacyclovir does not have any place in HIV
prevention. This does not imply, however, that there is
no interaction between HSV-2 infection and HIV-1
infection. The evidence – though observational – that
HSV-2 enhances the transmission of HIV is overwhelm-
ing. The problem lies in the lack of biomedical
interventions that can substantially reduce the incidence
and prevalence of HSV-2 infection. Meanwhile, valuable
lessons have been learned from these trials and we have
made progress in our understanding of the mechanisms
underlying the increased vulnerability to HIV-1 infection
associated with HSV-2 infection.
Suppressive therapy with acyclovir had a beneficial effect
on disease progression in HIV/HSV-2 co-infected
subjects. However, this benefit was rather modest and
cost-effectiveness analyses will have to be done to assess
whether acyclovir can have a place in the management of
HIV-infected patients in low- and middle-income
countries [25].
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